Restricted accessResearch articleFirst published online 2025-1
Exploring the Link Between Exogenous Thyroid Hormones and Dementia Symptoms: A Real-World Disproportionality Analysis of FDA Adverse Event Reporting System
A growing body of evidence indicates a strong association between exogenous thyroid hormone (ETH) and brain health. Establishing the potential relationship between ETH therapy and dementia symptoms is crucial for patients with thyroid disorders.
Objective:
In this study, we investigate the potential association between ETH therapy and dementia symptoms by exploring the Food and Drug Administration Adverse Event Reporting System (FAERS) database.
Methods:
Disproportionality analysis (DPA) was conducted using postmarketing data from the FAERS repository (Q1 2004 to Q4 2023). Cases of dementia symptoms associated with ETH therapy were identified and analyzed through DPA using reporting odds ratios and information component methods. Dose and time-to-onset analyses were performed to assess the association between ETH therapy and dementia symptoms.
Results:
A total of 9889 cases of ETH-associated symptoms were identified in the FAERS database. Dementia accounted for a consistent proportion of adverse drug reactions each year (3.4%-6.3%). The DPA indicated an association between ETH therapy and dementia symptoms, which remained significant even across sex, age, and indications. The median time-to-onset of dementia symptoms was 7.5 days, and the median treatment time was 40.5 days. No significant dose-response relationship was observed.
Conclusion and relevance:
This study provides evidence for a link between ETH therapy and dementia. Clinicians are therefore advised to exercise vigilance, conduct comprehensive monitoring, and consider individualized dosing to mitigate potential reactions to ETH drug administration.
KleinIOjamaaK.Thyroid hormone and the cardiovascular system. N Engl J Med. 2001;344(7):501-509. doi:10.1056/NEJM200102153440707
2.
van HeemstD. The ageing thyroid: implications for longevity and patient care. Nat Rev Endocrinol. 2024;20(1):5-15. doi:10.1038/s41574-023-00911-7
3.
TaylorPNAlbrechtDScholzA, et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol. 2018;14(5):301-316. doi:10.1038/nrendo.2018.18
4.
PizzatoMLiMVignatJ, et al. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet Diabetes Endocrinol. 2022;10(4):264-272. doi:10.1016/S2213-8587(22)00035-3
5.
BouldHPanickerVKesslerD, et al. Investigation of thyroid dysfunction is more likely in patients with high psychological morbidity. Fam Pract. 2012;29(2):163-167. doi:10.1093/fampra/cmr059
6.
TaylorPNIqbalAMinassianC, et al. Falling threshold for treatment of borderline elevated thyrotropin levels-balancing benefits and risks: evidence from a large community-based study. JAMA Intern Med. 2014;174(1):32-39. doi:10.1001/jamainternmed.2013.11312
7.
MetwalleyKAFarghalyHS.Subclinical hyperthyroidism in children. J Pediatr Endocrinol Metab. 2023;36(4):342-345. doi:10.1515/jpem-2022-0534
8.
TanSYChubbSAPFlickerL, et al. Changes in thyroid function and evolution of subclinical thyroid disease in older men. Clin Endocrinol (Oxf). 2024;100:170-180. doi:10.1111/cen.14997
9.
Drugs for hypothyroidism. Med Lett Drugs Ther. 2023;65(1670):25-29. doi:10.58347/tml.2023.1670a
10.
KantorEDRehmCDHaasJSChanATGiovannucciEL.Trends in prescription drug use among adults in the United States from 1999-2012. JAMA. 2015;314(17):1818-1831. doi:10.1001/jama.2015.13766
11.
AdamsROhESYasarSLyketsosCGMammenJS.Endogenous and exogenous thyrotoxicosis and risk of incident cognitive disorders in older adults. JAMA Intern Med. 2023;183(12):1324-1331. doi:10.1001/jamainternmed.2023.5619
12.
SalehipourADolatshahiMHaghshomarMAminJ.The role of thyroid dysfunction in Alzheimer’s disease: a systematic review and meta-analysis. J Prev Alzheimers Dis. 2023;10(2):276-286. doi:10.14283/jpad.2023.20
13.
FolkestadLBrandtFLillevang-JohansenMBrixTHHegedüsL.Graves’ disease and toxic nodular goiter, aggravated by duration of hyperthyroidism, are associated with Alzheimer’s and vascular dementia: a registry-based long-term follow-up of two large cohorts. Thyroid. 2020;30(5):672-680. doi:10.1089/thy.2019.0672
14.
YeapBBAlfonsoHChubbSA, et al. Higher free thyroxine levels predict increased incidence of dementia in older men: the Health in Men Study. J Clin Endocrinol Metab. 2012;97(12):E2230-E2237. doi:10.1210/jc.2012-2108
15.
AubertCEBauerDCda CostaBR, et al. The association between subclinical thyroid dysfunction and dementia: the Health, Aging and Body Composition (Health ABC) Study. Clin Endocrinol (Oxf). 2017;87(5):617-626. doi:10.1111/cen.13458
16.
ChakerLWoltersFJBosD, et al. Thyroid function and the risk of dementia: the Rotterdam study. Neurology. 2016;87(16):1688-1695. doi:10.1212/WNL.0000000000003227
17.
ZhouJWeiZChenS, et al. Movement disorders associated with antiseizure medications: a real-world disproportionality analysis of the Food and Drug Administration Adverse Event Reporting System. Br J Clin Pharmacol. 2023;89(11):3389-3400. doi:10.1111/bcp.15836
18.
ZhouJWeiZXuBLiuMXuRWuX.Pharmacovigilance of triazole antifungal agents: analysis of the FDA adverse event reporting system (FAERS) database. Front Pharmacol. 2022;13:1039867. doi:10.3389/fphar.2022.1039867
19.
RenWWangWGuoY.Analysis of adverse reactions of aspirin in prophylaxis medication based on FAERS database. Comput Math Methods Med. 2022;2022:7882277. doi:10.1155/2022/7882277
20.
YuRJKrantzMSPhillipsEJStoneCAJr.Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS). J Allergy Clin Immunol Pract. 2021;9(2):819-829.e2. doi:10.1016/j.jaip.2020.09.021
21.
HuYBaiZTangY, et al. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a pharmacovigilance study with data from the U.S. FDA adverse event reporting system. J Diabetes Res. 2020;2020:3695101. doi:10.1155/2020/3695101
22.
LiuLChenJWangLChenCChenL.Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database. Front Endocrinol (Lausanne). 2022;13:1043789. doi:10.3389/fendo.2022.1043789
23.
TadaKMaruoKIsogawaNYamaguchiYGoshoM.Borrowing external information to improve Bayesian confidence propagation neural network. Eur J Clin Pharmacol. 2020;76(9):1311-1319. doi:10.1007/s00228-020-02909-w
24.
RothmanKJLanesSSacksST.The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13(8):519-523. doi:10.1002/pds.1001
25.
ZhaiYYeXHuF, et al. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system. J Immunother Cancer. 2019;7(1):286. doi:10.1186/s40425-019-0754-2
26.
NorénGNHopstadiusJBateA.Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2013;22(1):57-69. doi:10.1177/0962280211403604
27.
van PuijenbroekEPBateALeufkensHGLindquistMOrreREgbertsAC.A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3-10. doi:10.1002/pds.668
28.
XiaSGongHZhaoY, et al. Tumor lysis syndrome associated with monoclonal antibodies in patients with multiple myeloma: a pharmacovigilance study based on the FAERS database. Clin Pharmacol Ther. 2023;114(1):211-219. doi:10.1002/cpt.2920
29.
SauzetOCarvajalAEscuderoAMolokhiaMCorneliusVR.Illustration of the Weibull shape parameter signal detection tool using electronic healthcare record data. Drug Saf. 2013;36(10):995-1006. doi:10.1007/s40264-013-0061-7
30.
AndersonNBorlakJ.Correlation versus causation? pharmacovigilance of the analgesic flupirtine exemplifies the need for refined spontaneous ADR reporting. PLoS ONE. 2011;6(10):e25221. doi:10.1371/journal.pone.0025221
31.
FusaroliMRaschiEGiunchiV, et al. Impulse control disorders by dopamine partial agonists: a pharmacovigilance-pharmacodynamic assessment through the FDA adverse event reporting system. Int J Neuropsychopharmacol. 2022;25(9):727-736. doi:10.1093/ijnp/pyac031
32.
RaschiEFusaroliMArdizzoniAPoluzziEDe PontiF.Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment. Breast Cancer Res Treat. 2021;186(1):219-227. doi:10.1007/s10549-020-06001-w
33.
von ElmEAltmanDGEggerM, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4(10):e296. doi:10.1371/journal.pmed.0040296
34.
RabbitoADulewiczMKulczyńska-PrzybikAMroczkoB.Biochemical markers in Alzheimer’s disease. Int J Mol Sci. 2020;21(6):1989. doi:10.3390/ijms21061989
35.
ScheltensPDe StrooperBKivipeltoM, et al. Alzheimer’s disease. Lancet. 2021;397(10284):1577-1590. doi:10.1016/S0140-6736(20)32205-4
36.
Sawicka-GutajNZawalnaNGutPRuchałaM.Relationship between thyroid hormones and central nervous system metabolism in physiological and pathological conditions. Pharmacol Rep. 2022;74(5):847-858. doi:10.1007/s43440-022-00377-w
37.
De LeoSLeeSYBravermanLE.Hyperthyroidism. Lancet. 2016;388(10047):906-918. doi:10.1016/S0140-6736(16)00278-6
38.
YuJ.Trends in the incidence of thyroid cancer among US persons from 2000 to 2019. Eur J Cancer Prev. 2024;33(1):5-10. doi:10.1097/CEJ.0000000000000827
39.
MirahmadMMansourAMoodiM, et al. Prevalence of thyroid dysfunction among Iranian older adults: a cross-sectional study. Sci Rep. 2023;13(1):21651. doi:10.1038/s41598-023-49085-2
40.
ZhouJWeiZZhengY, et al. Disproportionality analysis of lenvatinib-caused gastrointestinal perforation in cancer patients: a pharmacovigilance analysis based on the US Food and Drug Administration adverse event reporting system. J Clin Pharmacol. 2023;63:1133-1140. doi:10.1002/jcph.2312
41.
Jurado-FloresMWardaFMooradianA.Pathophysiology and clinical features of neuropsychiatric manifestations of thyroid disease. J Endocr Soc. 2022;6(2):bvab194. doi:10.1210/jendso/bvab194
42.
ToboreTO.On the central role of mitochondria dys-function and oxidative stress in Alzheimer’s disease. Neurol Sci. 2019;40(8):1527-1540. doi:10.1007/s10072-019-03863-x
43.
BavarsadKHosseiniMHadjzadehMASahebkarA.The effects of thyroid hormones on memory impairment and Alzheimer’s disease. J Cell Physiol. 2019;234(9):14633-14640. doi:10.1002/jcp.28198
44.
QuinlanPHorvathAEckerströmCWallinASvenssonJ.Altered thyroid hormone profile in patients with Alzheimer’s disease. Psychoneuroendocrinology. 2020;121:104844. doi:10.1016/j.psyneuen.2020.104844
45.
SakaedaTTamonAKadoyamaKOkunoY.Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10(7):796-803. doi:10.7150/ijms.6048
46.
KhaleelMAKhanAHGhadziSMSAdnanASAbdallahQM.A standardized dataset of a spontaneous adverse event reporting system. Healthcare (Basel). 2022;10(3):420. doi:10.3390/healthcare10030420
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
